P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
Kristine A. Frerichs(National Cancer Center), Niels W.C.J. van de Donk(Oncode Institute), Ilse Kuipers(Amsterdam University Medical Centers), Ajay K. Nooka(Emory University), María‐Victoria Mateos(Hospital Clínico San Carlos), Cesar Rodriguez(Wake Forest University), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Alfredo Perales‐Puchalt(The Wistar Institute), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Sonja Zweegman(Vrije Universiteit Amsterdam), Margaret Doyle(Janssen (Ireland)), Katherine Chastain(Janssen (United States)), Sandy Kruijswijk(Amsterdam University Medical Centers), Kaz Groen(Amsterdam University Medical Centers), Sheri Skerget(Translational Genomics Research Institute), Tom Martin(UCSF Helen Diller Family Comprehensive Cancer Center), Christie P.M. Verkleij(Dutch Cancer Society)
Cited by 5
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k